FDA Determines Regulatory Review Period for CRESEMBA Patent Extension

Summary

The US Food and Drug Administration has officially approved the regulatory review period for the patent extension of CRESEMBA, a drug approved under the new drug application 207501, following a submission to the US Patent and Trademark Office.